**Egypt**

**Population 2018** 98 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>12 (11–14)</td>
<td>12 (11–14)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.1 (0.049–0.17)</td>
<td>0.1 (0.05–0.18)</td>
</tr>
<tr>
<td>MDR-RR-TB incidence**</td>
<td>0.28 (0.2–0.38)</td>
<td>0.29 (0.21–0.38)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.42 (0.38–0.47)</td>
<td>0.43 (0.39–0.48)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.031 (0.014–0.054)</td>
<td>0.03 (0.01–0.06)</td>
</tr>
</tbody>
</table>

**Estimated proportion of TB cases with MDR/RR-TB, 2018**

- % tested with rapid diagnostics at time of diagnosis 32%
- % with known HIV status 41%
- % pulmonary 54%
- % bacteriologically confirmed**°° 94%
- % children aged 0–14 years 6%
- % women 35%
- % men 59%

**Total cases notified** 8 448

---

**Universal health coverage and social protection**

- TB treatment coverage (notified/estimated incidence), 2018 68% (61–77)
- TB patients facing catastrophic total costs 4% (3–4)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018
- HIV-negative TB mortality 0.42 (0.38–0.47)
- HIV-positive TB mortality 0.03 (0.01–0.06)

**Notified cases by age group and sex, 2018**

<table>
<thead>
<tr>
<th>Incidence</th>
<th>Females</th>
<th>Males</th>
<th>0-4</th>
<th>5-14</th>
<th>15-24</th>
<th>25-34</th>
<th>35-44</th>
<th>45-54</th>
<th>55-64</th>
<th>65+</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-negative TB mortality</td>
<td>1000</td>
<td>2000</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance **°° **
  - New cases 90%
  - Previously treated cases 88%
- Laboratory-confirmed cases* MDR/RR-TB: 142, XDR-TB: 0
- Patients started on treatment* ** MDR/RR-TB: 80, XDR-TB: 0
- MDR-R/RR-TB cases tested for resistance to second-line drugs 38

**Treatment success rate and cohort size**

- New and relapse cases registered in 2017 86% 8 053
- Previously treated cases, excluding relapse, registered in 2017 45% 142
- HIV-positive TB cases registered in 2017 91% 53
- MDR/RR-TB cases started on second-line treatment in 2016 86% 86
- XDR-TB cases started on second-line treatment in 2016 0

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment 22% (20–24)
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

**TB financing, 2019**

- National TB budget (US$ millions)

---

*Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

°°° Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-04-26

Data: www.who.int/tb/data